New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based Recommendations
Authors
Harausz, EGarcia-Prats, A
Seddon, J
Schaaf, H
Hesseling, A
Achar, J
Bernheimer, J
Cruz, A
D'Ambrosio, L
Detjen, A
Graham, S
Hughes, J
Jonckheere, S
Marais, B
Migliori, G
McKenna, L
Skrahina, A
Tadolini, M
Wilson, P
Furin, J
Issue Date
2017-05-15Submitted date
2017-07-24
Metadata
Show full item recordAbstract
It is estimated that 33,000 children develop multidrug-resistant tuberculosis (MDR-TB) each year. In spite of these numbers, children and adolescents have limited access to the new and repurposed MDR-TB drugs. There is also little clinical guidance for the use of these drugs and for the shorter MDR-TB regimen in the pediatric population. This is despite the fact that these drugs and regimens are associated with improved interim outcomes and acceptable safety profiles in adults. This review fills a gap in the pediatric MDR-TB literature by providing practice-based recommendations for the use of the new (delamanid and bedaquiline) and repurposed (linezolid and clofazimine) MDR-TB drugs and the new shorter MDR-TB regimen in children and adolescents.Publisher
American Thoracic SocietyPubMed ID
27854508Language
enDescription
We regret that this article is behind a paywall.ISSN
1535-4970ae974a485f413a2113503eed53cd6c53
10.1164/rccm.201606-1227CI